Published in Br J Haematol on April 01, 2007
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J (2013) 1.03
Assessing response of myeloma bone disease with diffusion-weighted MRI. Br J Radiol (2012) 0.92
Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol (2010) 0.87
Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol (2012) 0.86
Multiple myeloma. Cancer Imaging (2010) 0.85
Multiple myeloma: a review of imaging features and radiological techniques. Bone Marrow Res (2011) 0.82
Non Secretory Multiple Myeloma With Extensive Extramedullary Plasmacytoma: A Diagnostic Dilemma. Iran J Radiol (2015) 0.80
Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma. Cancer Res Treat (2014) 0.76
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. Br J Haematol (2016) 0.76
Oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature. Case Rep Hematol (2014) 0.75
Multiple myeloma: imaging evaluation of skeletal disease. J Community Hosp Intern Med Perspect (2013) 0.75
State-of-the-Art Management of Complications of Myeloma and Its Treatment. Adv Hematol (2010) 0.75
Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study. BMJ Open (2013) 0.75
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol (2005) 4.27
Endobronchial ultrasound-guided transbronchial needle aspiration prevents mediastinoscopies in the diagnosis of isolated mediastinal lymphadenopathy: a prospective trial. Am J Respir Crit Care Med (2012) 3.01
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood (2010) 2.33
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood (2004) 2.31
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. Ugeskr Laeger (2009) 2.03
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol (2010) 1.57
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood (2007) 1.32
Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax (2006) 1.24
Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol (2005) 1.18
Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol (2004) 1.14
The influence of pelvic tilt on acetabular orientation and cover: a three-dimensional computerised tomography analysis. Hip Int (2013) 0.98
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis (2009) 0.98
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol (2007) 0.92
C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol (2008) 0.91
Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol (2014) 0.90
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol (2010) 0.89
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica (2009) 0.88
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol (2007) 0.88
Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum (2006) 0.88
Evaluation of retained testes in adolescent girls and women with complete androgen insensitivity syndrome. Radiology (2013) 0.87
Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann Hum Genet (2007) 0.87
A test of performance of breast MRI interpretation in a multicentre screening study. Magn Reson Imaging (2006) 0.87
Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol (2013) 0.87
Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol (2010) 0.87
Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration. Eur J Haematol (2013) 0.84
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. Am J Hematol (2015) 0.84
Genetic variation in C-reactive protein (CRP) gene may be associated with risk of systemic lupus erythematosus and CRP concentrations. J Rheumatol (2008) 0.83
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer (2012) 0.82
Re-transplantation after bortezomib-based therapy. Br J Haematol (2011) 0.82
Radiology of the resurfaced hip. Skeletal Radiol (2011) 0.81
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol (2010) 0.81
Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis. Leuk Lymphoma (2012) 0.81
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer (2009) 0.81
Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet (2007) 0.80
Percutaneous minimally invasive stereotactic primary radiotherapy for breast cancer. Lancet Oncol (2002) 0.80
Characterization of potential CD138 negative myeloma "stem cells". Haematologica (2012) 0.80
The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Exp Hematol (2007) 0.79
Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leuk Lymphoma (2013) 0.79
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer (2010) 0.79
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP. Ann Hematol (2010) 0.78
Pain reduction after percutaneous vertebroplasty for myeloma-associated vertebral fractures. Dan Med J (2014) 0.78
Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use. Eur J Haematol (2012) 0.77
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol (2014) 0.77
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol (2013) 0.76
A rare cause of severe hepatomegaly with an improving outcome. BMJ Case Rep (2014) 0.75
Biological variation of free light chains in serum. Clin Chim Acta (2013) 0.75
Detection of cryptic MLL insertions using a commercial dual-color fluorescence in situ hybridization probe. Cancer Genet Cytogenet (2003) 0.75
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol (2013) 0.75
[Determination of light chains in serum]. Ugeskr Laeger (2010) 0.75
[A syndrome of chronic ataxic polyneuropathy, ophtalmoplegia, IgM paraprotein, cold agglutinins and anti-disialosyl antibodies can cause diplopia in patients with chronic sensory polyneuropathy]. Ugeskr Laeger (2012) 0.75
Bone bruises: definition, classification and significance. Br J Hosp Med (Lond) (2007) 0.75
Remnant functioning cervical tissue after laparoscopic removal of cavitated noncommunicating rudimentary uterine horn. J Minim Invasive Gynecol (2012) 0.75
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival. Eur J Haematol (2014) 0.75
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol (2010) 0.75
Bilateral cerebellopontine angle lesions not always NF2: diagnostic pitfall. Br J Neurosurg (2011) 0.75
Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. Eur J Haematol (2014) 0.75
Contact lenses and corrective flying spectacles in military aircrew--implications for flight safety. Aviat Space Environ Med (2005) 0.75
[Polyneuropathy associated with monoclonal gammopathy of undetermined significance]. Ugeskr Laeger (2012) 0.75